

Assessment of Cord Blood Hepcidin levels in Preeclampsia and Eclampsia

Thesis

*Submitted as Partial Fulfillment of Master Degree
in Obstetrics and Gynecology*

By

Dalia Rashad Mohamed Mahmod

M.B.B., Ch - 2009

*Resident of Obstetrics and Gynecology
Elgalaa Teaching Hospital*

Under Supervision of

**Prof. Mohamed Ashraf Mohamed
Farouk Kortam**

*Professor of Obstetrics and Gynecology
Faculty of Medicine- Ain Shams University*

Dr. Moustafa Ibrahim Ibrahim

*Assistant Professor of Obstetrics and Gynecology
Faculty of Medicine- Ain Shams University*

Dr. Ahmed Sherief Abdel Hamid

*Lecturer in Obstetrics and Gynecology
Faculty of Medicine- Ain Shams University*

**Faculty of Medicine
Ain Shams University**

2015



Acknowledgement

First of all I thank Allah for his great mercy and help to complete this work,

I would like to express my deepest gratitude and sincere appreciation to Prof. Mohamed Ashraf Mohamed Farouk Kortam, Professor of Obstetrics and Gynecology Faculty of Medicine Ain Shams University for his continuous encouragement and valuable advice to bring this work to light.

I would like to express my deep gratitude to Dr., Moustafa Ibrahim Ibrahim; Assistant Professor of Obstetrics and Gynecology and Dr., Ahmed Sherief Abdel Hamid; Lecturer of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University. Without their continuous guidance, support, encouragement and assistance, the accomplishment of this work wouldn't have been possible.

I would like to express my sincere appreciation to Dr. Rania Hamdy Elkabrety lecturer of Clinical Pathology, Faculty of Medicine, Ain Shams University for her kind encouragement and great help in performing this study.

Finally, I can never forget to express the profound thanks and appreciation to all my friends who helped me with special thanks to my family, for their great effort and support they offered in performing this work.

Introduction

Preeclampsia is a pregnancy-specific disease characterized by hypertension and proteinuria. It is a significant cause of maternal and fetal morbidity and mortality worldwide (*Kathleen et al., 2012*). During embryogenesis and development, the fetus obtains oxygen and nutrients from the mother via placental microcirculation. The placenta is a unique organ that develops and differentiates per se, and that regulates fetal growth and maternal condition in the entire course of gestation. Several life-threatening diseases during pregnancy, as preeclampsia and eclampsia, are closely associated with placental dysfunction. Cumulative studies have suggested that preeclampsia is associated with hypoxic micromilieu of fetoplacental site with decreased utero-placental blood flow, *Furuya et al. (2008)* thus producing a state of chronic fetal hypoxia in utero (*Hu et al., 2012*).

Hepcidin, a small polypeptide produced by hepatocytes is mainly expressed in the liver (*Liu et al., 2012*). Other possible sites of hepcidin are heart, brain, choroid plexus, lung and placenta (*Muehlenbachs et al., 2007; Ganz, 2004*). Hepcidin is the main regulator of iron

absorption and its tissue distribution. Pathologically increased hepcidin levels cause or contribute to iron-restrictive anemia including anemia associated with some cancers, inflammation in hereditary hemochromatosis and ineffective erythropoiesis (**Ganz T and Nemeth, 2011**). Hypoxia suppresses hepcidin, thereby promoting intestinal iron uptake and release from internal stores. While hypoxia-inducible factor (HIF), a central mediator of cellular adaptation to hypoxia, directly regulates renal and hepatic erythropoietin (EPO) synthesis under hypoxia, the molecular basis of hypoxia/HIF-mediated hepcidin suppression in the liver remains unclear (**Nicolas et al., 2002**).

Hypoxia caused by respiratory insufficiency in preterm infants was also associated with decreased hepcidin production (**Gun et al., 2013**). The presence of placental hepcidin has been documented (**Lindheimer et al., 2008**). However, knowledge about the other functions of hepcidin in neonates is limited (**O'Brien et al., 2005**). Compared hepcidin and erythropoietin levels in the cord blood of neonates with meconium-stained amniotic fluid (MSAF) to levels obtained from age-, body mass index- and gravidity-matched neonates with clear amniotic fluid and concluded that meconium release in low-risk

Aim of the Work

The aim of the current study is to compare hepcidin levels in cord blood of neonates in pregnant women with preeclampsia during labor to the levels of in cord blood of neonates with normal pregnant women.

Research question:

Is there a significant relationship between hepcidin cord blood level and preeclampsia

Exclusion criteria:

1. Women with other medical disorders.
2. Congenital fetal malformation.
3. Intrauterine growth restriction due to any cause other than preeclampsia.
4. Meconium stained liquor.
5. Rhesus isoimmunization (Coombs positive).
6. Smoking.

Ethical issues:

The protocol of the study will be presented for approval by the ethical committee of the department of gynecology and obstetrics of Ain shams maternity hospital.

Consent process:

The population sample under study will be instructed about research protocol and informed consent are granted from each participant before randomization.

Study design

Type of study:

Case control study.

Methodology:

1. A detailed history and thorough physical examination of all participants will be carried out the degree of preeclampsia will be assessed.
2. A complete laboratory investigation for preeclampsia will be done, i.e.
 - A complete blood picture with platelet count.
 - Liver functions test.
 - Renal function test.
 - 24 hours urine protein collection.
 - Coagulation profile.
3. The umbilical cord will double clamped and blood samples will collected from by needle puncture just after delivery.
4. All deliveries will performed by the vaginal route.

Intervention:

Cord blood samples of 67 neonates following term gestations (≥ 37 weeks' gestation) with preeclampsia and eclampsia (group 1) and 67 maternal age-, body mass index- and gravidity-matched controls with no evidence of preeclampsia or eclampsia (group 2) will analyzed in this study.

Laboratory method:

Umbilical cord blood sample 50-100 μ L will be taken into vacutainer tubes and centrifuged. Serum samples will then be stored in aliquots at -70°C until the testing period. Serum hepcidin levels will be measured by enzyme-linked immunosorbent assay.

The hepcidin kit was a sandwich enzyme immunoassay for the in vitro quantitative measurement of hepcidin in human serum plasma and other biological fluids. The minimal detectable concentrations of hepcidin (sensitivity of the assays) is 1.17 ng/ml for Detection range of 4.69-300ng/ml.

Data collection:

- Demographic data, delivery outcomes and laboratory evaluations will be recorded and compared in both groups.
- Data or results which are collected after arrangement in suitable manner by a process known as processing of data may be manual or computerized .
- These data should be confidentially protected.

Presentation of data:

Data will be collected, tabulated, then analyzed on a personal computer using IBM© SPSS© Statistics version 21 (IBM© Corp., Armonk, NY).

The Kolmogorov-Smirnov goodness of fit test will be used to test the normality of numerical data distribution. Normally distributed numerical data will be presented as mean and SD and differences between the two groups will be compared with the independent-samples t test.

Skewed numerical data will be presented as median and interquartile range and inter-group differences will be compared non-parametrically using the Mann-Whitney U test.

Qualitative data will be presented as number and percentage and the chi square test or Fisher's exact test, when appropriate, will be applied for comparison of the two groups.

All P values will be two-tailed. $P < 0.05$ will be considered statistically significant.

Sample size calculation:

The required sample size has been calculated using the G*Power version 3.1.7 software (Heinrich Heine

Universität, Institut für Experimentelle Psychologie,
Düsseldorf, Germany).

The primary outcome measure will be the difference between the two study groups as regards the level of hepcidin in cord blood.

Two recent studies reported that the level of hepcidin in cord blood is not normally distributed in the population (*Briana et al., 2013*). The former study reported that the median (range) level of hepcidin in the cord blood of appropriate-for-age (AFA) neonates was 17.85 (4.75–69.2) ng/ml compared with 20.2 (2.82–50.91) ng/ml in neonates with intrauterine growth retardation (IUGR) (*Briana et al., 2013*).

The latter study reported that the median (range) level of hepcidin in the cord blood of neonates with clear amniotic fluid was 27.4 (4.3–82.5) ng/ml compared with 40.2 (2.3–115.7) ng/ml in neonates with meconium-stained amniotic fluid (MSAF) (*Gun Eryilmaz et al., 2013*).

Thus, it is estimated that a sample size of 67 patients in each study group would achieve a power of 80% (type II error = 0.2) to detect a medium effect size (d) of 0.5 as regards the primary outcome measure.

References

American College of Obstetricians and Gynecologists.

ACOG Practice Bulletin No. 95: Anemia in pregnancy.
Obstet Gynecol 2008; 112: 201–207.

Briana DD, Boutsikou T, Baka S, Boutsikou M, Stamati

L, Hassiakos D, Gourgiotis D, Malamitsi-Puchner A.

Perinatal role of hepcidin and iron homeostasis in full-term intrauterine growth-restricted infants. Eur J Haematol. 2013; 90(1): 37-44.

Furuya M, Ishida J, Aoki I, Fukamizu A.

Pathophysiology of placentation abnormalities in pregnancy-induced hypertension. . Vasc Health Risk Manag. 2008;4(6):1301-13.

Ganz T and Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011; 62: 347-60.

Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol 2004; 11: 251–254.

Gun Eryilmaz O, Tavit B, Turan S, Yumusak O,

Doganay M, Uzunlar O, Akar S, Eyi EG. Hepcidin and erythropoietin measurements in the cord blood of neonates with meconium-stained amniotic fluid. J Obstet Gynaecol Res. 2013; 39(1):175-9.

Gun Eryilmaz O, Tavil B, Turan S, Yumusak O, Doganay M, Uzunlar O, Akar S, Eyi EG. Hepcidin and erythropoietin measurements in the cord blood of neonates with meconium-stained amniotic fluid. *J Obstet Gynaecol Res.* 2013; 39(1): 175-9.

Hu XQ, Xiao D, Zhu R, Huang X, Yang S, Wilson SM, Zhang L. Chronic hypoxia suppresses pregnancy-induced upregulation of large-conductance Ca^{2+} activated K^{+} channel activity in uterine arteries. *Hypertension.* 2012; 60(1): 214-22.

Kathleen A.P., Jessica M.S., Daniel L.J., Laura C.S., Danny J.S. Preeclampsia: multiple approaches for a multifactorial diseases. *Dis Model Mech.* 2012; 5(1): 9-18.

Lindheimer MD, Taler SJ, Cunningham FG. Hypertension in pregnancy. *J Am Soc Hypertens.* 2008; 2(6): 484-94.

Liu Q, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. *J Clin Invest.* 2012; 122(12): 4635-44.